Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Trial of Consolidation Tarlatamab + Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer (LS-SCLC)

NCT07637513 is registered in ClinicalTrials.gov with PrECOG, LLC. as lead sponsor.

NCT NCT07637513
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07637513 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Trial of Consolidation Tarlatamab + Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer (LS-SCLC)
Lead sponsor
PrECOG, LLC.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
January 31, 2027
Completion date
June 30, 2038
Enrollment
430 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

limited stage small-cell lung cancer